Icteric form of hepatitis a in childen with food allergy treatment method

FIELD: medicine.

SUBSTANCE: invention belongs to medicine, notably to hepatology, and relates to viral hepatitis A treatment in children with food allergy in acute phase of disease. On admission to hospital patient receives usual complex therapy of hepatitis, complemented with antihistaminic drugs - suprastin or tavegil, and enzymatic drugs - pancreatin or mesym - forte. Suprastin or tavegil is administered ј - 1 tablet after meal two times a day during 7-10 days. Pancreatin or mezym-forte is administered Ѕ-1 tablet 3 times a day during 14-18 days.

EFFECT: method fastens children recovery and reduces frequency of disease residual effects.

1 ex, 6 tbl, 4 dwg

 

The present invention relates to medicine, namely to drug therapy, and can be used in Hepatology for the treatment of viral hepatitis a (HAV) in children with food Allergy (PA) in acute period of the disease.

Viral hepatitis (SH) in children, especially the CAA, are among the common diseases. The CAA is registered not less than 2/3 of all children suffering from acute VG (BRIC NI, Lytkina, I.N., Sobolev V.I. et al. Clinical-epidemiological characteristics and main trends of hepatitis a // Leche doctor. - 2001. No. 5 - 6. - P.54-57). According to some authors, the clinical picture of HAV in children at the present time reveals a clear tendency to increase the severity of the disease, prolonged jaundice, increase in the frequency of cholestatic forms (Raises A.R., Grondin, A., Nikitina, T.S. et al. The study of viral hepatitis in clinical Department of children // Zhur. microbiol. - 1997 - No. 6. - P.84-86).

It is well known that the reactivity of the organism is essential in the formation of the infectious process. The literature data indicate a significant influence on the formation of severe and adverse outcomes VG children their age, sex, chronic diseases of the parents, the pathology of pregnant women and newborns, early artificial feeding, brought the child is related to the hepatitis diseases, and factors of environmental pollution (Bondarenko A.L. Clinical, immunological and genetic analysis of hepatitis b virus /Disease. And INF. bol. - 1999. No. 1. - Pp.42-46; Kalagina PS Features of the course and outcomes of viral hepatitis a and b in children with food allergies // Dis... Kida. the honey. Sciences. - 1987. - 209 C.).

Allergy has become one of the important medical and social problems of the last decade in connection with the global prevalence and intensive growth of allergic disease /Khaitov R.M P.M., Bulova A.V., Ilyin NI Epidemiology of allergic diseases in Russia // Immunology. - 1998. No. 3. - P.4-9.; Zauli D., R. Bortolotti, A. Grassi et al. Changes in atopy over 25 years: atopy now affects wider age range // BMJ. - 2005. - Vol. 331. No. 7512. - P.352/. Most disturbing are reports of increases in allergic diseases among children. The share of food Allergy (PA) among patients with atopy ranges from 15% to 40% /Ladoga HP, Borovik Christmas eve, Roslavtseva E.A. et al. Food intolerance in children: clinical forms, approaches to diagnosis and treatment // Pediatrics. - 1998. No. 2. - P.77-82/. Allergic diseases are currently treated with positions altered immunological reactivity. Thus, atopy, including PA, in the case of layering infectious process extremely unfavorable for its current and complete. These data lead to the search schema pathogenetic therapy VG, partly the e HAV in children with PA, they can enhance their complete clinical and biochemical recovery.

Therapy HAV in children - the main provisions stipulated by the order of the USSR Ministry of health No. 408 from 12.07.1989. According to the order of the USSR Ministry of health No. 408 from 12.07.1989, light icteric form the CAA does not require medication, it is quite adequate basic therapy, including mode, diet, protect the liver from additional loads. By order of the USSR Ministry of health No. 408 from 12.07.1989 moderately icteric form CAA in most cases can be treated in the same way, only in some cases it is necessary injecting a means of detoxification, intravenous crystalloid fluids fluids (5% glucose solution, aqueous salt solutions: acesol, latosol, dial) with the addition of ascorbic acid and colloidal solutions (reopoliglyukin, gemodez).

A prototype of the invention is selected known method of treatment of HAV in children with PA, including combination therapy in accordance with the order of the USSR Ministry of health No. 408 from 12.07.1989.

The known method of treatment is as follows. The patient in the first 7-10 days of jaundice prescribe bed rest, later pruposely before discharge from hospital. The diet of a sick child HAV high-grade, easily digestible, high-calorie. The ratio of proteins, fats and carbohydrates 1:4:4-5. A large part of the daily diet of proteins in the acute is erode disease is injected with dairy and vegetable products (cottage cheese). For the whole period of the disease from the diet exclude extractive substances, meats, marinades, high-melting fats, spices (Table # 5). In addition, in children with PA exclude products that cause the child clinical worsening (Table No. 5 - individual). In the first 3-5 days of receipt of the child in the hospital a few limited amount of fat (Table No. 5A - individual). In addition to nutrition children receive drinking: simony tea (100-200), compote of dried fruits (200-400), mineral water (100-250). When moderately icteric form the CAA, in some cases, from the moment of admission to the hospital for 3-5 days children parenterally administered 5% glucose solutions (150-400), aqueous salt solutions, atesol (100-200), less colloidal solutions: reopoliglyukin, gemodez (100-200). In the stage of convalescence after the normalization of the color of feces and urine after the onset of the crisis - all children receive broth choleretic herbs - corn columns with stigmas for 2 weeks 1-2 tablespoons (15-30 ml) 3 times a day before meals.

However, the known method of treatment of children with icteric forms of HAV from PA, has the following disadvantages. Namely, when the icteric form CAA (light and heavy) in children with PA for the treatment of the authors of the proposed method of treatment ascertained reliably significant differences in the slowing down of time their is azdarawlenne against children in the control group (p< 0.0002 and p<0,0043), greater frequency of residual disease in these children, their tendency to prolonged convalescence and prolonged course of the disease (p<0,0009-0,04). In addition, in children with PA at a well known method of treatment, we observed the preservation reliably significant differences of complex biochemical indicators of blood bilirubin and enzymes against standards (comparison group - healthy) after mild icteric form of the disease, and after moderate icteric form of the disease throughout the observation period to six months after discharge from hospital (p<0,0000 and p<0,0028). In the end we can conclude that there is a method of treatment of jaundice forms HAV in children with PA often does not solve the problems of recovery without residual disease and complications, and in some cases, the danger remains protracted course of the disease in these children.

The task of the invention is to accelerate the timing of a recovery from PA from icteric forms HAV reduction in the incidence of residual disease.

The problem is solved in that in the known method of treatment of jaundice forms HAV in children with PA, including the combined therapy, in addition to the child enters the hospital in the acute period of the disease, prescribe antihistamines and enzymatic drugs antihistamines of destinations the t 1/4-1 after pill meal 2 times a day for 7-10 days, enzyme preparations on1/2-1 tablet before meals 3 times a day for 14-18 days.

We used single and daily doses of antihistamines and enzyme preparations in the treatment of jaundice forms HAV in children with PA stipulated by the literature of the State Pharmacopoeia.

The present invention meets the criterion of "novelty", as in the process of patent information research has not identified the sources of patent and scientific and technical information prejudicial to the novelty of the proposed method.

The present invention meets the criteria of the invention "inventive step"as the sources of literature not discovered the ways of treatment of viral hepatitis a in children with PA with the essential features of the invention.

Antihistamines such as suprastin and tavegil, and enzymatic preparations - Pancreatin and Mezim - long used in drug therapy. According to the literature, is known for their use in the treatment of allergic diseases in both adults and children (Balabolkin I.I. Modern concept of the pathogenesis and principles of treatment of allergic diseases in children // Pediatrics. - 2003. No. 6. - S-102; Nogales AM Allergic syndrome in chronic digestive diseases // Klinicheskaya. - 2001. No. 11. - P.65-71). Reported on the effectiveness of enzyme therapy for chronic viral hepatitis In children (Shabunina EII et al. Systemic enzyme therapy in pediatric practice // inform. letter. - Moscow - 2005. 13 C.). In the available literature we did not observe the results of the study of therapeutic interventions in children of patients with CAA with PA.

The present invention allows to obtain a positive effect.

Just the observation of 297 children with icteric forms HAV: easy - 212 children and moderate - 85 children. About half of them were girls (49,0%). Food allergies in children has been documented data out of the Cabinet, where they were on the observation before admission to the infectious diseases hospital. In all cases (100%) was observed presentability simultaneously to two or three foods. The predominant clinical form of the disease was urticaria (79.8 per cent), less atopic dermatitis (19,2%) and bronchial asthma, combined with urticaria (1,0%). All observed children, the sick icteric forms the CAA with PA (297 children)received combination therapy of a disease in accordance with the order of the USSR Ministry of health No. 408 from 12.07.89. According to the method of the prototype therapy VG received 161 child with PA (group I), 131 of them in mild icteric form of the disease and 30 children with moderate jaundice is the form of the disease (control). In addition, 136 children, patients with icteric forms HAV: 81 children with mild icteric form of the disease, 55 children with moderate icteric form of the disease in the acute period of the disease received chemotherapy according to the proposed method of treatment. Of these, in addition antihistamines - suprastin or tavegil - (I-A group) received 22 child: 12 children with mild icteric form of the disease and 10 children with moderate icteric form of the disease. Enzyme preparations - Pancreatin or Mezim - (I-B group) received 66 children: 41 children with mild icteric disease and 25 children with moderate form of the disease. Antihistamines - suprastin or tavegil simultaneously with enzyme preparations - Pancreatin or Mezim - (I-AB group) received 48 children: 28 children with mild icteric form of the disease and 20 children with moderate form of the disease. Group of patients HAV from PA who received additional therapy in the acute period of the disease (I-A, I-B and I-AB) within the clinical form of the disease by age and sex, were identical with the group of children who received the combined therapy control (group I). Norm (the comparison group) presented 15 healthy children of the same age and gender.

The diagnosis of HAV put on generally accepted clinical, laboratory and epidemiological tests, confirming the etiology of the disease in all cases detection in si is orode blood of specific antibodies to hepatitis a virus (anti-HAV Ig M) enzyme-linked immunosorbent assay (ELISA). Clinical variant, the severity of the disease, the nature of the course and the clinical outcome was evaluated in accordance with order No. 408 from 12.07.89. The discharge of children from hospital was performed as their recovery in accordance with the order of the USSR Ministry of health No. 408 from 12.07.89. Monitoring and marked by the CAA conducted within six months after discharge from hospital, sequentially through one, three and six months.

The survey results are processed on the computer using the software package "Statistika 6.0" using discriminant analysis functions, calculation of student's criterion, Fisher and confidence factor to the observed differences (p).

The effectiveness of the treatment methods were primarily assessed by the rate of recovery observed groups of children with mild and moderate icteric form of the CAA. Namely in terms of normalization of the seven main clinical and laboratory parameters of the disease, i.e. in terms of normalization of child's health (duration of intoxication), color of feces and urine (day of onset of stroke), coloration of the skin and mucous membranes (the day of the disappearance of jaundice), liver size and indicators of biochemical blood test for bilirubin and enzymes (total bilirubin blood, Alat and thymol turbidity tests) in children with PA, received during the acute icteric forms HAV (light and heavy) in addition antihistamine the courthouse square - suprastin or tavegil (table 1), the enzyme preparations - Pancreatin or mesim (table 2), antihistamines - suprastin or tavegil simultaneously with enzyme preparations - Pancreatin or mesim (table 3). As can be seen from the tables, the time normalization of the main clinical and laboratory parameters easy icteric form of HAV in children with PA, received during the acute period of the disease additionally antihistamines suprastin or tavegil (table 1), the enzyme preparations - Pancreatin or mesim (table 2) and antihistamines - suprastin or tavegil simultaneously with enzyme preparations - Pancreatin or mesim (table 3), on all seven indicators were significantly lower than in children with PA in the treatment of disease (p<0,001-0,05). According to table 1 in children with PA at moderate icteric form HAV received during the acute period of the disease additionally antihistamines (suprastin or tavegil), only the terms of the normalization condition and coloration of the skin, mucous membranes were significantly less against children received treatment with the prototype (p<0.001 to 0.01). At the same time in children with PA at moderate icteric form HAV received during the acute period of the disease advanced enzyme preparations - Pancreatin or mesim (table 2), the enzyme preparations - Pancreatin or Mezim - along with antihistamie the tion drugs - the suprastin or tavegilum (table 3), we noted substantial improvements in terms of normalization of the majority of clinical and laboratory indices of disease, p<0.001 to 0.01.

According to tables 1, 2 and 3 the normalization of the child's health, color of feces and urine, color of skin and mucous membranes, liver size, laboratory parameters of the biochemical analysis of a blood on a bilirubin and enzymes in children with PA, undergoing icteric form CAA especially easy icteric form of the disease who received advanced during the acute period of the disease antihistamines (suprastin or tavegil), enzymes (Pancreatin or Mezim), antihistamines (suprastin or tavegil) simultaneously with enzyme preparations (Pancreatin or Mezim), occurred at 2-8 days earlier than in children with complex therapy disease.

Figure 1 shows the timing of normalization (days of illness) of the seven main clinical and laboratory parameters easy icteric form CAA, figure 2 - moderately icteric form of the disease in children with PA depending on the treatment. Namely, the time normalization of well-being of the child is the duration of the intoxication - (1), the size of the liver (2), and the activity of Alt in the serum (3), indicator thymol samples of blood serum (4), the timing of the normalization of the color of feces and urine - the day of occurrence of accidents (5), coloration of the skin and mucous membranes - the duration of jaundice (6), total bilirubin serum (7). The diagrams (figure 1 and figure 2) group I - children who received only the complex therapy of the disease, I And a group of children who received in addition to the complex therapy antihistamines (suprastin or tavegil), I-B group - children who received in addition to the complex therapy of enzymes (Pancreatin or Mezim), I-AB group of children who received in addition to the complex therapy antihistamines (suprastin or tavegil) in combination with enzyme preparations (Pancreatin or Mezim). In mild icteric form HAV in children with PA, according to the diagram (Fig 1) shorter time to normalize all seven of the studied clinical and laboratory parameters of the disease we noted during the addition of complex therapy antihistamines (I-group), enzyme preparations (I-B group), antigistaminny drugs in combination with enzyme preparations (I-AB group). When moderately icteric form HAV in children with PA, according to the diagram (figure 2), and lowest in terms of normalization of most of the seven studied clinical and laboratory parameters of the disease, we observed in addition to comprehensively therapy of enzyme preparations (I-B group) and enzyme preparations in combination with antihistamines (I-AB group).

Thus, we noted the most significant effect of enzyme preparations (Pancreatin or Mezim), enzyme preparations (Pancreatin or Mezim) simultaneously with antihistamines (suprastin or tavegilum) in terms of the normalization of the main clinical and laboratory parameters icteric forms HAV (light and heavy) in children with PA, manifested in accelerating their recovery.

In addition, we studied the effectiveness of the proposed methods of treatment in acute icteric forms HAV in children with PA on long-term outcomes of the disease. Below is the frequency of recovery and residual effects of the CAA (post-hepatitis hepatomegaly) in children with PA, undergoing icteric form of the disease (mild and moderate) six months after discharge from hospital in the complex therapy in the acute period of the disease and additional therapy antihistamines - suprastin or tavegilum (table 4), enzyme preparations - Pancreatin or mesim (table 5), antihistamines - suprastin or tavegilum - enzymatic drugs - Pancreatin or Mezim - at the same time (table 6). According to the tables in children with PA, undergoing mild icteric form CAA and received in the acute period of the disease in addition to comprehensive therapy antihistamines - suprastin or she is evil (table 5), enzyme preparations - Pancreatin or mesim (table 6), antihistamines - suprastin or tavegil simultaneously with enzyme preparations - Pancreatin or mesim (table 7), clinical and laboratory recovery six months after discharge from hospital were recorded significantly more often against children with PA in the treatment of disease, and residual effects of the disease - hepatomegaly - less (p<0,001-0,05). According to table 4, in children with PA at moderate icteric form HAV received during the acute period of the disease additionally antihistamines (suprastin or tavegil), recovery six months after discharge from hospital against children who received therapy prototype (complex), were also reported more often, and residual effects of the disease (hepatomegaly) - rarely, but without significantly significant difference between groups (p>0,05). At the same time in children with PA at moderate icteric form HAV received during the acute period of the disease advanced enzyme preparations - Pancreatin or mesim (table 5), enzyme preparations - Pancreatin or Mezim - along with antihistamines - suprastin or tavegilum (table 6) against the children who received therapy prototype (complex), we noted significantly significant differences in the frequency of recovery and residual Bo is esni (hepatomegaly) six months after discharge from hospital (p< 0,01). Consequently, we have developed the most significant positive effect of enzyme preparations (Pancreatin or Mezim), enzyme preparations (Pancreatin or Mezim) simultaneously with antihistamines (suprastin or tavegilum) on the frequency of recovery of children with PA from icteric forms HAV (light and heavy). According to tables 4, 5 and 6, the recovery at the end of follow - up six months after discharge from hospital - children with PA in complex therapy of jaundice forms HAV had 2/3-3/4 of children with mild icteric form of the disease it was registered in 67,2% of cases, moderate-yellowish - shape in 73,3% of cases. Residual effects of the CAA (hepatomegaly) in complex therapy of jaundice forms had more than1/4children with PA: mild icteric form of the disease they had 32.8% of children with moderate to severe icteric form - 26.7% of the children. At the same time, the recovery from jaundice forms HAV in children with PA, received during the acute period of the disease therapy on the proposed method of treatment, was observed in the majority of cases, and the residual effects of the disease (post-hepatitis hepatomegaly) - in rare cases mild icteric form of disease: with one child received during the acute period of illness additionally, the enzymes Pancreatin (I-B group, 2,4%), and one child received in sharp the period of illness is advanced enzyme preparations at the same time with antihistamine - Pancreatin and suprastin (I-AB group, 3,6%).

Table 4
Outcomes icteric form of viral hepatitis a in children with food allergies in the complex therapy - I and additional therapy antihistamines - I-A six months after discharge from hospital (%).
DiseaseThe outcome of the diseaseA group of children
I n=131PI-A n=12
ach%ach%
lightRecovery8867,2<0,0512100
Residual effects - hepatomegaly4332,8<0,05--
moderate A group of children
I n=30PI-A n=10
ach%ach%
Recovery2273,3>0,0510100
Residual effects - hepatomegaly826,7>0,05--

Table 5
Outcomes icteric form of viral hepatitis a: light and heavy in children with food allergies in the complex therapy - I and additional therapy enzyme preparations - I-B six months after discharge from hospital (%).
DiseaseThe outcome of the diseaseA group of children
I n=131 PI-B n=41
ach%ach%
lightRecovery8867,20,0014097,6
Residual effects - hepatomegaly4332,8<0,00112,4
medium-heavyA group of children
I n-30P1-B n=25
ach%ach%
Recovery2273,30,0125100
Residual phenomenon is s - hepatomegaly826,70,01--

32,8
Table 6
Outcomes icteric form of viral hepatitis a: light and heavy in children with food allergies in the complex therapy - I and additional therapy antihistamines and enzyme preparations - I-AB six months after discharge from hospital (%).
DiseaseThe outcome of the diseaseA group of children
I n=131PI-AB n=28
ach%ach%
lightRecovery8867,20,0012796,4
Residual effects - hepatomegaly430,00113,6
moderateA group of children
In=30PI-AB n=20
ach%ach%
Recovery2273,30,0120100
Residual effects - hepatomegaly826,70,01--

Thus, according to tables 4, 5 and 6, reducing the frequency of residual phenomena (hepatomegaly) in children with PA, received the advanced acute icteric forms HAV (light and heavy) antihistamines (tavegil or suprastin), enzymes (Pancreatin or Mezim), antihistamines (suprastin or tavegil) simultaneously with fermentee drugs (Pancreatin or Mezim) against children, received therapy for prototype, respectively: 32,8% and 26.7%; 30.4% and 26,7%; 29.2% 26.7 percent. That is, the positive effect of therapy in acute icteric forms HAV in children with PA on the proposed method of treatment, reducing the frequency of residual disease (hepatomegaly) in long-term follow up (six months after discharge from the hospital), we noted more than 25%.

It should be noted substantial improvements in terms of normalization of complex biochemical indicators of blood bilirubin and enzymes in children with PA, undergoing icteric form CAA: light and heavy, received during the acute period of the disease therapy on the proposed method of treatment against children who received only the complex therapy. Comparing the set of indicators of the biochemical analysis of a blood on a bilirubin and enzymes each of the observed groups (group I; I-A group I-B group; I-AB group) for six months during the survey through 1-3-6 months after discharge from hospital and the comparison group - healthy (norms), we noted the timing of the disappearance of biochemical signs of HAV in children with PA under various schemes of pathogenetic therapy in acute icteric forms of the disease (mild and moderate). Figure 3 shows the timing of normalization of complex biochemical indicators of blood on bilir the bin and enzymes in mild icteric form HAV in children with PA depending on the treatment in the acute period of the disease for six months during the survey through 1-3-6 months after discharge from hospital, figure 4 - when moderately icteric form of the disease. In the drawings (figure 3 and figure 4) group I - children who received only the complex therapy of the disease, I And a group of children who received in addition to the complex therapy antihistamines (suprastin or tavegil), I-B group - children who received in addition to the complex therapy of enzymes (Pancreatin or Mezim), I-AB group of children who received in addition to the complex therapy antihistamines (suprastin or tavegil) in combination with enzyme preparations (Pancreatin or Mezim). As seen in the drawings, children with PA who underwent both light and moderate icteric form HAV received during the acute period of the disease only complex therapy (group I), for six months during the survey through 1-3-6 months after hospital discharge using a range of indicators of biochemical blood test for bilirubin and enzymes retained reliably significant differences with children in the comparison group (norm), respectively: p<0,0000 and p<0,0028. At the same time, children with PA, received during the acute HAV therapy on the proposed method of treatment is additionally antihistamines: suprastin or tavegil - (I-group), antihistamines: suprastin or tavegil simultaneously with enzyme preparations: Pancreatin or Mezim - (I-AB group, after discharge from the hospital on a range of indicators of biochemical blood test for bilirubin and enzymes were not significantly significant difference with children in the comparison group (norm) in light (p<0,1589 and p<0,2248)and moderately icteric form of the disease (p<0,1342 and p<0,0830). That is, the children of these groups (I-A group I-AB group)who underwent icteric form CAA (light and heavy), a month after hospital discharge using a range of indicators of biochemical blood test for bilirubin and enzymes had no significant differences with children in the comparison group (norm). Thus, in children with PA, undergoing icteric form CAA (light and heavy), with additional therapy in the acute period of the disease antihistamines (I-group), antihistamines in combination with enzyme preparations (I-AB group) had the most significant reduction of the normalization of complex biochemical indicators of blood bilirubin and enzymes after their discharge from the hospital (Fig 3. and figure 4). As seen in the drawings, children with PA, received during the acute HAV advanced enzyme preparations - Pancreatin or mesim (I-B group), after discharge from hospital using a range of indicators of biochemical blood test for bilirubin and enzymes retained reliably significant differences about the Yves children in the comparison group (norms) for one month after discharge from hospital as mild, and at moderately icteric form of the disease, respectively: p<0,0366 and p<0,0217. Further 3-6 months after discharge from hospital, as seen in the drawings, these children (I-B group)who underwent icteric form CAA (light and heavy), using a range of indicators of biochemical blood test for bilirubin and enzymes lost significant differences with children in the comparison group (norm). So, in children with PA, undergoing icteric form CAA (light and heavy), received during the acute period of the disease in addition to the complex therapy of enzyme preparations against children who received only the combined therapy, there was also a significant reduction in terms of normalization of complex biochemical indicators of blood bilirubin and enzymes after their discharge from hospital.

Consequently, it is possible to talk about a significant positive effect of enzyme preparations (Pancreatin or Mezim), antihistamines (suprastin or tavegila), in children with PA at icteric forms HAV (light and heavy), shorten the time normalization of biochemical blood test for bilirubin and enzymes after discharge from the hospital for 3-5 months, against children with PA, received during the acute icteric forms of the disease (mild and moderate) therapy for prototype treatment.

Thus, pre the proposed method for the treatment of jaundice forms HAV (light and heavy) in children with PA in acute period of the disease - additional therapy antihistamines (suprastin or tavegila) simultaneously with enzyme preparations (Pancreatin or Mezim allows to significantly reduce the time of recovery and increase the frequency of their clinical and laboratory recovery.

The proposed method of treatment is as follows. When enrolling a child with PA in the hospital with jaundice forms the CAA (in the acute phase of the disease), other than combined therapy in accordance with the order of the USSR Ministry of health from 12.07.89, appoint additional antihistamines (suprastin or tavegil) and enzymes (Pancreatin or Mezim) simultaneously, antihistamines prescribed for1/4-1 after pill meal 2 times a day for 7-10 days, enzyme preparations on1/2-1 tablet before meals 3 times a day for 14-18 days.

An example of a specific implementation of the method of treatment of jaundice forms HAV a child with PA is given in the form of extracts from the history.

Example. Katya O., 7 years old (case history No. 3782, clinical laboratory chart - 3), was admitted for treatment in the hospital 28.11.92 on the 6th day of illness, the 1st day of jaundice.

The final clinical diagnosis: Viral hepatitis And mild icteric form, acute. Food polyvalent Allergy atopic dermatitis in the acute stage. About lomenie - acute pancreatitis (reactive).

The girl fell ill acutely, weakness, body temperature rise up to 38°, nausea, and abdominal pain. On the 6th day of the disease is marked dark urine and light stool, yellowish coloration of the skin and mucous membranes. On the same day (6th day of the disease) a district doctor, the girl was sent for treatment at the hospital.

When receiving treatment in hospital 28.11.92 (6-day sickness) the child's condition is moderate: the girl is sluggish, the body temperature of 37.5°, skin and mucous membranes with a slight yellowish tinge to the sclera ictericia. On the face and elbow pityriasis scales with traces of scratching. Language moderately white furred, wet. Submandibular, cervical and axillary lymph nodes are small, painless, not connected with the subjacent tissues. In the lungs vesicular breathing with a frequency of 20 to 1 minute. Heart sounds slightly muffled, rhythmic frequency 82 in 1 minute. Abdomen moderately swollen, painless. The liver is palpated 1.0-1.5-2.0 cm from under the costal arch. The consistency of liver elasticity. Spleen not palpated. Feces bright, dark urine.

In the biochemical analysis of a blood on a bilirubin and enzymes from 29.11.92 bilirubin total 61,00 mmol/l, direct - 30,00 mmol/l, indirect - 31,00 mmol/l; Alat-6,9 mmol/l; thymol turbidity test - 15 items Found cytolytic, excretory-biliary and inflammation with ndrome. In the serum in ELISA (29.11.92) detected anti-HAV-Ig M (+). Amylase urine from 29.11.92 (7-day sickness) - 128 units Marked with involvement in the pathological process of the pancreas - pancreatitis (reactive). On the 11th day of illness (03.12.92) urine amylase 16%

From the anamnesis of life it is known that the child's parents and immediate family healthy. A girl born from the second, normal pregnancy, in urgent physiological childbirth, without asphyxia. To breast the baby is attached to 12 hours after birth, breast milk received 4 months, then mix. Complementary foods (porridge) in the child's diet was introduced with 4 months. One month after the introduction of complementary foods the girl mentioned the rash transient nature. In the future - after a year - rash transient nature of the girl transformed in atopic dermatitis. With 3 years the child is registered at the allergist. The girl has a diagnosed food Allergy for dessert, egg white and milk. Recent exacerbation of food allergies in children are marked for the week prior to treatment in the hospital. The girl suffers frequent colds, chickenpox rubella, and varicella. A month before admission to the hospital, the child had contact with a patient with HAV in school. Any medical diagnostic injections in the year prior to the present illness in girls is not installed.

Hospital virgins who cka, in addition to the basic therapy with the exception of the sweet food, eggs and milk, received an antihistamine (suprastin) and enzyme preparation (mesim). Both drugs the child received from admission to the hospital (6-day sickness), suprastin for 10 days, and Mezim - for 16 days. As a result of the treatment the girl's condition improved on the 10th day of the disease, normalization of body temperature, color of the feces and urine, skin and mucous membranes were observed respectively on the 7th, 13th and 22nd days of the disease. Normalization of liver size is stated on the 24th day of illness, and index of Alt in the biochemical analysis of blood, on the 27th day of illness. The child was discharged from the hospital after 22 days on the 28th day of illness with recovery.

After discharge from the hospital she received conventional Wellness mode reconvalescent VG (Ministry of health of the USSR from 12.07.89.). Through 1-3-6 months after discharge from hospital the mother of the child did not report any variances to the little girl feels. Indicators of biochemical blood test for bilirubin and enzymes of the child after discharge from the hospital remained within normal limits. Thus, the girl after discharge from the hospital confirmed clinical and biochemical recovery from the CAA.

Clinical and laboratory indicators and: Periods of illness - time normalization:
Acute (28 days)Convalescence - months after discharge from hospital:
136>6
Fever5 days
Intoxication10 days
Color of feces and urine14 days
The color of skin and mucous22 days
Liver enlargement26 days
Intercurrent diseases
Worsening food allergies-
Bilirubin total, mol/l61789
associated, mol/l30000
Alat, mol/l6,90,30,20,25
Thymol turbidity test unit5212
Amylase urine, ed128
Defeat (complication):
- pancreas-
- biliary:
- stomach and duodenum

Figure 3. Clinical and laboratory chart history No. 3782. Kato 7 years. The final clinical diagnosis: Viral hepatitis And mild icteric form, acute. Food polyvalent Allergy atopic dermatitis in the acute stage.

As can be seen from the clinical example the patient easy icteric form CAA with PA, received the advanced acute period of the disease an antihistamine (suprastin) simultaneously with Fe is the elemental drug (mesim), the disease was characterized by a smooth, accelerating recovery, no residual disease at the time of discharge from hospital and complications of the disease in the period of convalescence.

Method for the treatment of jaundice forms of viral hepatitis a in children with food allergies, including the combined therapy, characterized in that it further admission of the child to the hospital in the acute period of the disease, prescribe antihistamines - suprastin or tavegil - and enzyme preparations - Pancreatin or Mezim-Forte, with suprastin or tavegil appoint 1/4-1 tablet after a meal 2 times a day for 7-10 days, Pancreatin or Mezim-Forte appoint 0.5-1 tablet 3 times a day for 14-18 days.



 

Same patents:

FIELD: chemistry.

SUBSTANCE: present invention relates to phenylalanine derivatives and their pharmaceutically acceptable salts. In formula (1) R11 is a hydroxyl group, an alkoxyl group having 1-6 carbon atoms, which can be substituted with a methoxy group, cycloalkoxyl group having 3-6 carbon atoms, or a benzyloxy group; R12 and R13 each independently represents a hydrogen atom, alkyl group having 1-6 carbon atoms, cycloalkyl group having 3-6 carbon atoms, acetyl group or methyloxycarbonyl group, or N(R12)R13 is a 1-pyrrolidinyl group, 1-piperidinyl group, 4-morpholinyl group; R14 is a methyl group; R1' is a hydrogen atom, fluorine atom; X1 is -CH(R1a)-, -CH(R1a)CH(R1b)-, -CH(R1a)CH(R1b)CH(R1c)-, -N(R1a)CH(R1b)CH(R1c)-, -OCH(R1a)CH(R1b)-, -OCH(R1a)CH(R1b)CH(R1c)- or 1,3-pyrrolidinylene, where R1a, R1b, each independently represents a hydrogen atom or a methyl group, and R1c is a hydrogen atom; Y11 and Y12 represent any of the combinations (CI, Cl), (CI, Me), (CI, F). Invention also relates to phenylalanine derivatives of formulae (2)-(14), given in the formula of invention.

EFFECT: obtaining a pharmaceutical composition having antagonistic effect on α4-integrin, containing a phenylalanine derivative as an active ingredient, a α4-integrin antagonist and a therapeutic agent.

65 cl, 51 tbl, 244 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula (I) capable of bonding with S1P receptor (specifically EDG-6, preferably EDG-1 and EDG-6), its non-toxic water-insoluble salts or its methyl or ethyl ester.

EFFECT: obtaining compounds which can be used in preventing and/or treating graft rejection, graft-versus-host diseases, autoimmune diseases and allergic diseases.

11 cl, 66 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics and concerns a complex containing mequitazine, cyclodextrin and a reaction agent where the molar ration within the system mequitazine/cyclodextrin/the reaction agent and mequitazine/the reaction agent is 1/1 - 1/10 and water-dissolution rate of mequitazine being a part of the complex measured for an aqueous solution with mequitazine concentration 2 g/l at 35°C after 15 minutes of stirring, makes more than 50% at pH 9, to a method for preparing said complex and a based pharmaceutical composition.

EFFECT: invention provides improved solubility of mequitazine.

20 cl, 1 dwg, 1 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to tetrahydropyridoindole derivatives of general formula , where R1, R2, R3 and R4 independently represent hydrogen; C1-C5alkyl, which can be optionally substituted and represents trifluoromethyl if C1-C5alkyl is substituted; C1-C3alkoxy or halogen, and R5 is C1-C6alkylcarbonyl, C1-C5alkylcarbamoyl, C1-C5alkoxycarbonyl, C2-C5alkenylcarbonyl, C3-C6cycloalkylcarbonyl, C3-C6cycloalkyl(C1-C3)alkylcarbonyl, C3-C6cycloalkylcarbamoyl, C3-C6cycloalkylthiocarbamoyl, phenylcarbonyl or phenyl(C1-C3)alkylcarbonyl, where the phenyl residue in these two groups contains one, two, three or four substitutes, independently selected from a group comprising C1-C4alkyl, C1-C3alkoxy, halogen, trifluoromethyl and trifluoromethoxy, monosubstituted with a C3-C6cycloalkyl group, or monosubstituted with a phenyl group which in turn is substituted with a C1-C3alkyl group; phenyl(C1-C3)alkoxycarbonyl, phenylcarbamoyl or phenylthiocarbamoyl (where these two groups are optionally independently monosubstituted with a C1-C5alkyl group or halogen atoms); phenyl(C1-C3)alkylcarbamoyl, phenyl(C1-C3)alkylthiocarbamoyl, biphenylcarbamoyl, naphthylcarbonyl, naphthyl(C1-C3)alkylcarbonyl or naphthylcarbamoyl (where the naphthyl residues in these three groups are optionally monosubstituted with substitutes independently selected from a group comprising C1-C3alkyl, C1-C3alkoxy and halogen); fluorenylcarbonyl, optionally substituted with an oxo group, fluorenyl(C1-C3)alkoxycarbonyl; or 5-9-member heteroarylcarbonyl groups containing one or two heteroatoms, independently selected from a group comprising oxygen, nitrogen and sulphur, where the said groups can be substituted with one or two groups independently selected from C1-C3alkyl and halogen, provided that if R1, R2, R3, R4 are hydrogen, R5 is not ethoxycarbonyl or tert-butoxycarbonyl, or salt thereof. The invention also relates to a pharmaceutical composition based on the compound of formula I and to use of the compound in preparing a medicinal agent.

EFFECT: obtaining novel tetrahydropyridoindole derivatives which have CRTH2 receptor antagonistic activity.

14 cl, 14 tbl, 171 ex

FIELD: medicine.

SUBSTANCE: there are selected strains Lactobacillus capable to raise IL-10 level and simultaneously to reduce TGF-beta-2 level in human breast milk to be applied with the products containing cells of selected strains to improve human milk for breast feeding. Selected strains and said products containing cells of selected strains are applied to increase of levels of anti-inflammatory cytokine IL-10 in human breast milk and reduce risk of allergy development in a breast-fed infant, to improve anti-inflammatory activity of human breast milk and to reduce simultaneously causal factors.

EFFECT: invention provides decreased TGF-beta-2 level in milk that leads to reduced risk of mastitis development in a nursing mother.

22 cl, 1 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to chemical-pharmaceutical industry and concerns preparation of a solid dosage form for treating respiratory allergosis and arresting nasopharynx edema. There is offered a tableted medical product containing mixed active substance and excipient. As an active substance, it contains a corticosteroid preparation, and according to the invention, additionally contains an active substance presented with adrenaline or noradrenaline. The inside of a tablet contains the corticosteroid preparation, while the exterior contains adrenaline. As a corticosteroid preparation it contains dexamethasone, prednisolone or celestone. Also there is offered a tableted medical product that contains mixed active substance and excipient. As an active substance, it contains a corticosteroid preparation, and additionally contains active substances presented with adrenaline or noradrenaline, and also aminophylline and mesatone. The tablet is multilayered, its inside contains mesatone, the layer containing aminophylline adjoins the inside, then the layer containing the corticosteroid preparation is executed, and the exterior contains adrenaline or noradrenaline.

EFFECT: there is offered a tableted medical product.

4 cl, 3 ex

FIELD: medicine.

SUBSTANCE: external skin preparation contains as active components a ferrous compound and a compound chosen from 5-aminolevulin acid, salt of 5-aminolevulin acid, ester of 5-aminolevulin acids, ester of salt of 5-aminolevulin acids, N-acyl-5-aminolevulin acids, salts of N-acyl-5 aminolevulin acid and ester of N-acyl-5-aminolevulin acid. The ferrous compound is chosen from iron (II) citrate, sodium-iron citrate, ammonium-iron citrate, iron acetate, iron oxalate, iron (II) succinate, sodium-iron succinate and citrate, iron (II) pyrophosphate, iron (III) pyrophosphate, heme iron, iron dextrane, iron lactate, iron (II) gluconate, sodium-iron diethylene triaminepentaacetate, ammonium-iron diethylene triaminepentaacetate, ethylenediaminetetraacetate sodium-iron ethylene aminpentaacetate, ammonium-iron ethylene aminpentaacetate, iron triethylene tetraamine, sodium-iron dicarboxymehtyl glutamate and ammonium-iron dicarboxymehtyl glutamate.

EFFECT: improved skin look, prevention or reduction of roughness, dryness, wrinkles, flabbiness, and pigment spots, efficient for atopic dermatitis.

16 cl, 2 ex, 2 dwg

FIELD: medicine.

SUBSTANCE: there is described thiomorpholine compound presented by formula (I) wherein the ring A represents benzene ring; the ring B represents benzene ring; R1 represents hydrogen atom, R2 represents C1-6-alkyl group; R3a and R3b are identical or different, each representing hydrogen atom or C1-6-alkyl group, and n represents an integer equal to 2, or its pharmaceutically acceptable salt. There is also described method for making the compound of formula (1), a pharmaceutical composition and application of the compound of formula (1) for making a medical product used for treatment and prevention of the disease chosen from inflammation, allergic diseases, pain, migraine, neuralgia, itch, cough, central nervous system diseases, alimentary organ diseases, nausea, vomiting and urological disorders.

EFFECT: compounds exhibits affinity to neurokinine-1 receptor.

6 cl, 4 tbl, 16 ex

FIELD: medicine.

SUBSTANCE: invention refers to compounds of formula I or formula II, to their pharmaceutically acceptable salts, enantiomers and diastereoisomers as metalloprotease inhibitors, and also to a pharmaceutical composition based thereon and to versions of application thereof. Said compounds can find application in treatment of the diseases mediated by activity of metalloproteases, Her-2 SHEDDASE, ADAM-10 and ADAM-17, such as arthritis, cancer, cardiovascular disorders, skin diseases, inflammatory and allergic conditions, etc. In general formula I or II: A represents CWNHOH; B represents CH2; G represents CH2; D represents oxygen; X represents CH2NRb; Y represents CH2; M represents C; U is absent or represents NRb; V is absent or represents phenyl, or 4-10-members heterocyclyl containing 1-2 heteroatoms chosen from N and S, substituted with 0-5 groups Re; U' is absent or represents C1-10alkylene, O or combinations thereof; V' represents H, C1-8alkyl, NRbRc, C6-10carbocyclyl substituted with 0-3 groups Re, or 5-14-members heterocyclyl containing 1-3 heteroatoms chosen from N, O and C substituted with 0-4 groups Re; Ra and Re, independently represents H, T, C1-8alkylene-T, C(O)NRa'(CRb'Rc')r-T, (CRb'Rc')r-O-(CRb'Rc')r-T, OH, Cl, F, CN, NO2, NRIRII, COORIV, ORIV, CONRIRII, C1-8halogenalkyl, C3-13carbocyclyl; Rb and Rc independently represents H, T, C1-6alkylene-T, C(O)O(CRb'Rc')r-T, C(O)(CRb'Rc')r-T, S(O)p(CRb'Rc')r-T; T represents H, C1-10alkyl substituted with 0-1 groups Rb'; C3-6carbocyclyl, 5-6-members heterocyclyl containing one oxygen atom; Ra' Rb' and Rc' independently represents H, ORIV or phenyl; R1 represents hydrogen; R2 represents hydrogen; R3 represents: (i) C1-10alkyl; (ii) 4-14-members heterocyclyl containing 1-3 nitrogen atoms optionally substituted with one or two substitutes chosen from C1-6alkyl, OR13, 5-10-members heterocyclyl containing 1-3 heteroatoms chosen from N O and C, or phenyl; (iii) NR16R17; R4 represents H; R4' represents H; R5' represents H; W represents oxygen; R13 represents C1-C6alkyl; R16 and R17 independently represents C1-C10alkyl or phenyl where each is optionally substituted with one C1-4alkyl; RI and RIIindependently represents H or C1-6alkyl; RIV represents C1-6alkyl; i is equal to 0; p is equal to 1 or 2 and r is equal to 0, 1 or 2; provided that a) a spiro ring represents a stable chemical base unit and b) NR8 and NRb do not contain neither N-N, nor N-O bonds.

EFFECT: higher efficiency of the composition and method of treatment.

54 cl, 1 tbl, 9 dwg, 284 ex

FIELD: chemistry.

SUBSTANCE: proposed phosphodiesterase 4 inhibitors are characterised by formulae II, III, V, VI, where X is CH or N; L is a single bond, -(CH2)nCONH-, -(CH2)nCON(CH2CH3)-, (CH2)nSO2, (CH2)nCO2 or alkylene, optionally substituted oxo or hydroxy; n assumes values from 0 to 3; R1 is optionally substituted alkyl; R3 - H, alkyl, cycloalkyl, alkoxyalkyl, optionally substituted phenyl, phenylalkyl, heterocyclyl, heterocyclylalkyl or cycloalkylalkyl; R4 and R5 represent alkyl; R6 - cycloalkyl, R7 is H; R8 is H, carboxy, alkoxycarbonyl, -CO-alkyl, optionally substituted alkyl.

EFFECT: new phosphodiesterase 4 inhibitors have improved properties.

55 cl, 30 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention concerns gastroenterology and represents a composition for treatment of pancreatic insufficiency containing microbial lipase, microbial protease and microbial amylase, and the ratio of lipase, protease and amylase in the specified composition makes approximately 1:1:0.15 USP units.

EFFECT: invention provides preparation of stable compositions with pancreatic enzymes, exhibiting maximum efficiency with minimum dosages and characterised with a common safety profile.

31 cl, 3 ex, 10 tbl, 7 dwg

FIELD: medicine; biotechnologies.

SUBSTANCE: method involves cultivation of strain-producer Penicillium canescens chosen from the group including: multicopy strain Penicillium canescens Abf6 (VKM № F-3935D), in gene abfA arabinoxylane-arabinofuranhydrolase Penicillium canescens containing arabinoxylanase and α-L-arabinofuranosidase activity, strain Penicillium canescens AbfB6 (VKM № F-3937D), in gene abfB2 α-L-arabinofuranosidase Penicillium canescens, multicopy strain Penicillium canescens AgLA33 (VKM № F-3936D), in gene aglA α-galactosidase Penicillium canescens containing both α-galactosidase and galactomannanase activity, strain Penicillium canescens AgLC4 (VKM № F-3934D), in gene aglC α-galactosidase Aspergillus awamori, multicopy strain Penicillium canescens FAE9 (VKM № F-3938D), in gene faeA feruloyl-esterase Penicillium funiculosum, multicopy strain Penicillium canescens XG9 (VKM № F-3939D), in gene xegA xyloglucanase Penicillium canescens.

EFFECT: extended range of enzymatic agents.

21 dwg, 1 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine and claims therapeutic material and therapeutic media based on it for purulo-necrotic wound treatment, as well as method of obtaining therapeutic material. Material includes activated textile carrier with trypsin, insulin and lysocim immobilised in it.

EFFECT: significant reduction of wound surface cleaning time, accelerated healing.

17 cl, 2 tbl, 9 ex

FIELD: medicine.

SUBSTANCE: there is prescribed gluten-free diet with eliminating cereals and additional order of protein: meat 100.0 g, cottage cheese 100.0 g, or sour cream 100.0 g daily. Creon is dosed 10000 ME at mealtime within 2 weeks. It is combined with physiotherapy exercises (PTE) within 20-30 minutes. During afternoon, every second day circular douche is applied at pressure 1.5-2 atmospheres, water temperature 36-35°C for 3-4 minutes within therapeutic course 10-12 procedures. On another days, radon baths are taken at water temperature 36°C, dosed 0.75 kBq/l for 8-10 minutes within therapeutic course 8-10 procedures. Electrophoresis is applied daily with 50% Dimexide solution (±) for small intestine projection by transverse technique, current density 0.05 mA/cm2 within 12-15 minutes within therapeutic course 10-12. The BAPs VC-20, VC-22, E-36, Gi-4 are exposed to red and infrared light daily within 1.5-2 minutes per each point within therapeutic course 10-12 procedures.

EFFECT: reduced specific immunologic markers of autoimmune intestine inflammations and cytokine generation level, normalised immune response of an organism, normalised hormonal and exchange processes.

2 ex, 2 tbl

FIELD: medicine; gastroenterology.

SUBSTANCE: antibacterial therapy is presented with selective decontamination using antiklebsiellic bacteriophage within 10 days. After that prebiotic therapy including Hylak Forte, enzymatic agent and Linex in therapeutic dosage is combined with probiotic introduction. For dysbacteriosis of I stage Bifiform is introduced in dose 1 capsule 2 times a day, for dysbacteriosis of II and III stages dose is 2 capsules 2 times a day, combined with Lactobacterinum 5 doses once a day. Thus medicinal plant tincture is introduced including silverweed rootstock, salvia leaves, milfoil herb, St. John's wort herb, elecampane rootstock with roots, tickseed herb, mint leaves, fennel fruits and buckthorn bark at component ratio respectively 2:2:2:2:2:2:2:2:1 dosed 1\3 of glass 3 times a day, 30 min before meal, within 4 weeks.

EFFECT: method has no contraindications and provides fast normalisation of gastrointestinal tract microflora.

1 tbl, 1 ex

FIELD: medicine; gynaecology.

SUBSTANCE: hormonal haemostasis is performed using complex oral contraceptive (COC) in dosage 1/2 tablet COC every 4-6 hours until metrorrhagia stops, and as well as during 1st day after. Further daily dose is reduced by 1/2 tablet every for next day. Whereas dosage 1 tablet a day is achieved, COC introduction is prolonged for another 21 days. After that within 3 months cerebrum compositum combined with coenzyme compositum dosed 2.2 ml is intramuscularly injected. Introduction of these agents is alternated with mixed cerebrum compositum and ubiquinone compositum injections dosed 2.2 ml. this therapy is combined with peroral introduction of lymphomyosote and nux vomyka-homaccord in dosage 10 drops 3 times a day, as well as hepel and neurohel dosed 1 tablet a day.

EFFECT: eliminated possibility of syndrome intravascular coagulation and disease relapse; reduced development of hormonal therapy by-effects; provided menstrual cycle normalisation for this contingent of patients.

2 ex

FIELD: medicine.

SUBSTANCE: method involves carrying out antibacterial therapy in standard mode. Wobenzyme and homeopathic drugs are additionally introduced into treatment course. Wobenzyme is given at a dose of 1 pill thrice a day 30 min before taking meals. Homeopathic drugs like Apis mellifika 6 China officinalis 6, Chelidonium mayus 6, Stannum 6, Sanguinaria Canadensis 6, Callium bronchicum 6, Carbo vegetabilis 6 are given at a dose of 5 grains thrice a day irrespective of food intake daily during the whole treatment course.

EFFECT: enhanced effectiveness of treatment; reduced risk of adverse side effects.

2 tbl

FIELD: medicine, ophthalmology.

SUBSTANCE: the present innovation deals with treating retinitis pigmentosa with the help of enzymes and applying a pharmaceutical composition as a kit applied for such therapy. The kit suggested contains the following enzymes: glutathione peroxidase, prolidase, glucose-6-phosphate dehydrogenase and, non obligatory, aldose reductase in aliquot portions and interactive quantities being acceptable to introduce the enzymes mentioned in accordance with the preset temporal sequence. The innovation enables to create the method for treating retinitis pigmentosa which provides the chance for gradual reconstruction of acuity, distinct picture and perception of colors.

EFFECT: higher efficiency of therapy.

13 cl, 1 tbl

FIELD: medicine, cosmetology.

SUBSTANCE: one should introduce enzymes-containing liposomes of DNAase activity into skin and/or subcutaneous fiber, moreover, one should apply multi-layer MLV-liposomes at their size ranged 500-2000 nm at temperature of phase transition of liposomal membrane being 30-60 C, moreover, one should deliver and deposit an enzyme into intercellular space, and as enzymes with DNAase activity one should apply endo- and/or exonucleases that destroy single and/or double stranded DNA. The innovation prevents the damage of intracellular DNA of alive skin cells and/or its adnexa and/or subcutaneous fiber.

EFFECT: higher efficiency of prophylaxis and correction.

4 ex, 4 tbl

The invention relates to medicine, in particular to the field of traumatology and orthopedics in the treatment of false joints and unjoining fractures of long bones

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of formula I , where R1 is C1-C7-alkyl; R2 is C1-C7-alkyl, C1-C7-haloalkyl, C3-C8-cycloalkyl; R3 is -NRaRb; possibly substituted phenyl, thiophenyl, furanyl, where the substitutes are selected from a group consisting of halogen, C1-C7-alkoxy, C1-C7-alkylsulphonyl and -C(O)O-C1-C7-alkyl; R4 is hydrogen or C1-C7-alkyl; R5 is hydrogen, halogen, C1-C7-alkyl, phenyl; or R5 together with R4 can form a ring selected from a group consisting of C5-C7-cycloalkyl, tetrahydrofuranyl, piperidine, tetrahydropyran, phenyl or pyridinyl, which can possibly be substituted with -C(O)O-C1-C7-alkyl; Ra and Rb together with the nitrogen atom to which they are bonded form piperidine; and to pharmaceutically acceptable salts thereof. The invention also relates to a medicinal agent based on the said compounds which has GABA-B receptor allosteric enhancement effect.

EFFECT: obtaining novel compounds and a medicinal agent based on the said compounds, which can be used in medicine for treating central nervous system disorders.

13 cl, 42 ex

Up!